Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. (22nd February 2011)

• Record Type: Journal Article
• Authors: Snir, A; Kessel, A; Haj, T; Rosner, I; Rozenbaum, M; Slobodin, G; Toubi, E
• Is Part Of: Annals of the rheumatic diseases. Volume 70(2011)Supplement 2
• Page Start: A57
• Page End: A58
• Publication Date: 2011-02-22
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2010.149005.1
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background and objectives: B cells function as regulatory cells by producing inhibitory cytokines such as transforming growth factor β (TGF-β) and interleukin 10 (IL-10). Human CD25high B cells were shown to secrete higher levels of IL-10 versus CD25low B cells, suggesting this subset of cells to be immune-regulatory. Tocilizumab, a monoclonal antibody that acts as an IL-6R antagonist thus inhibiting IL-6 activity, and its autocrine growth activity on B cells is currently used for treatment of rheumatoid arthritis (RA). Following this treatment, one might expect a reduction in B cell activity status, and on the other hand increase of their regulatory properties. Methods: Freshly purified B lymphocytes were isolated from 10 active RA patients, with inadequate response to methotrexate, at baseline and 3 months following add on tocilizumab. Clinical status was assessed by DAS 28 score and erythrocyte sedimentation rate (ESR). Using flow cytometry, B cells were stained for the expression of intracellular TGF-β, IL-10, membrane CD69, and MHC-II. These markers were assessed in primary (no-stimulated) CD25high B cells and expressed in MFI, with results given in mean ± SEM. Results: Three months following initiation of tocilizumab, the expression of intracellular TGF-β in CD25high B cells was significantly increased (from 5.2 ± 2.3 at baseline to 8.1 ± 2.8; p < 0.02); the expression of MHC-II on B cells was significantly reduced (from 9.1 ± 2.2 at baseline to 4.2 ± 0.4; p < 0.04). In addition, the expression of CD69 also decreased (from 7.6 ± 2.4 at baseline to 2.7 ± 0.7; p < 0.03). The expression of intracellular IL-10 was too low for comparison. These phenotypic B cell changes namely, the alteration in B cell activity and antigen presenting cell (APC) properties and the shift and/or expansion of the B cell subset with regulatory properties were found to occur in association with beneficial clinical outcome, namely DAS improvement from 6.8 ± 0.3 at baseline to 3.1 ± 0.4, p < 0.002, and ESR decrease from 44.4 ± 8.6 at baseline to 7.4 ± 2.3, p < 0.006. Conclusions: Our unique finding of a shift in B cell properties following tocilizumab treatment, namely the increase in TGF-β expression and the alteration in their activation status and APC properties in CD25high B cells, suggests that the induction/expansion of B regulatory cells may be one of the mechanisms by which tocilizumab may possibly produce its beneficial clinical effects.